131 related articles for article (PubMed ID: 37244566)
1. Therapeutic potential of glutaminyl cyclases: Current status and emerging trends.
Coimbra JRM; Moreira PI; Santos AE; Salvador JAR
Drug Discov Today; 2023 Oct; 28(10):103644. PubMed ID: 37244566
[TBL] [Abstract][Full Text] [Related]
2. A patent review of glutaminyl cyclase inhibitors (2004-present).
Coimbra JRM; Salvador JAR
Expert Opin Ther Pat; 2021 Sep; 31(9):809-836. PubMed ID: 33896339
[No Abstract] [Full Text] [Related]
3. Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease.
Vijayan DK; Zhang KYJ
Pharmacol Res; 2019 Sep; 147():104342. PubMed ID: 31288079
[TBL] [Abstract][Full Text] [Related]
4. An overview of glutaminyl cyclase inhibitors for Alzheimer's disease.
Coimbra JR; Sobral PJ; Santos AE; Moreira PI; Salvador JA
Future Med Chem; 2019 Dec; 11(24):3179-3194. PubMed ID: 31838899
[TBL] [Abstract][Full Text] [Related]
5. Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases.
Zhang Y; Wang Y; Zhao Z; Peng W; Wang P; Xu X; Zhao C
Eur J Pharmacol; 2022 Sep; 931():175178. PubMed ID: 35948163
[TBL] [Abstract][Full Text] [Related]
6. The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions.
Cynis H; Hoffmann T; Friedrich D; Kehlen A; Gans K; Kleinschmidt M; Rahfeld JU; Wolf R; Wermann M; Stephan A; Haegele M; Sedlmeier R; Graubner S; Jagla W; Müller A; Eichentopf R; Heiser U; Seifert F; Quax PH; de Vries MR; Hesse I; Trautwein D; Wollert U; Berg S; Freyse EJ; Schilling S; Demuth HU
EMBO Mol Med; 2011 Sep; 3(9):545-58. PubMed ID: 21774078
[TBL] [Abstract][Full Text] [Related]
7. Can small molecule inhibitors of glutaminyl cyclase be used as a therapeutic for Alzheimer's disease?
Wu H
Future Med Chem; 2017 Nov; 9(17):1979-1981. PubMed ID: 29076753
[TBL] [Abstract][Full Text] [Related]
8. Two insertion/deletion variants in the promoter region of the QPCTL gene are significantly associated with body weight and carcass traits in chickens.
Ren T; Li W; Liu D; Liang K; Wang X; Li H; Jiang R; Tian Y; Kang X; Li Z
Anim Genet; 2019 Jun; 50(3):279-282. PubMed ID: 30974000
[TBL] [Abstract][Full Text] [Related]
9. N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity.
Kehlen A; Haegele M; Böhme L; Cynis H; Hoffmann T; Demuth HU
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28739588
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of glutaminyl-peptide cyclotransferase(QPCT)in Scylla paramamosain and its role in Vibrio alginolyticus and white spot syndrome virus (WSSV) infection.
Wang Z; Sun B; Zhu F
Fish Shellfish Immunol; 2018 Jul; 78():299-309. PubMed ID: 29709591
[TBL] [Abstract][Full Text] [Related]
11. Role of glutaminyl cyclases in thyroid carcinomas.
Kehlen A; Haegele M; Menge K; Gans K; Immel UD; Hoang-Vu C; Klonisch T; Demuth HU
Endocr Relat Cancer; 2013 Feb; 20(1):79-90. PubMed ID: 23183267
[TBL] [Abstract][Full Text] [Related]
12. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.
Logtenberg MEW; Jansen JHM; Raaben M; Toebes M; Franke K; Brandsma AM; Matlung HL; Fauster A; Gomez-Eerland R; Bakker NAM; van der Schot S; Marijt KA; Verdoes M; Haanen JBAG; van den Berg JH; Neefjes J; van den Berg TK; Brummelkamp TR; Leusen JHW; Scheeren FA; Schumacher TN
Nat Med; 2019 Apr; 25(4):612-619. PubMed ID: 30833751
[TBL] [Abstract][Full Text] [Related]
13. Repurposing FDA-Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease.
Xu C; Zou H; Yu X; Xie Y; Cai J; Shang Q; Ouyang N; Wang Y; Xu P; He Z; Wu H
ChemistryOpen; 2021 Sep; 10(9):877-881. PubMed ID: 33377311
[TBL] [Abstract][Full Text] [Related]
14. Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.
Van Manh N; Hoang VH; Ngo VTH; Ann J; Jang TH; Ha JH; Song JY; Ha HJ; Kim H; Kim YH; Lee J; Lee J
Eur J Med Chem; 2021 Dec; 226():113819. PubMed ID: 34536669
[TBL] [Abstract][Full Text] [Related]
15. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
Schilling S; Zeitschel U; Hoffmann T; Heiser U; Francke M; Kehlen A; Holzer M; Hutter-Paier B; Prokesch M; Windisch M; Jagla W; Schlenzig D; Lindner C; Rudolph T; Reuter G; Cynis H; Montag D; Demuth HU; Rossner S
Nat Med; 2008 Oct; 14(10):1106-11. PubMed ID: 18836460
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.
Hartlage-Rübsamen M; Bluhm A; Piechotta A; Linnert M; Rahfeld JU; Demuth HU; Lues I; Kuhn PH; Lichtenthaler SF; Roßner S; Höfling C
Molecules; 2018 Apr; 23(4):. PubMed ID: 29673150
[TBL] [Abstract][Full Text] [Related]
17. Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors.
Xu C; Wang YN; Wu H
J Med Chem; 2021 May; 64(10):6549-6565. PubMed ID: 34000808
[TBL] [Abstract][Full Text] [Related]
18. Role of glutaminyl-peptide cyclotransferase in breast cancer doxorubicin sensitivity.
Xu B; Yang L; Yang L; Al-Maamari A; Zhang J; Song H; Wang M; Su S; Song Z
Cancer Biol Ther; 2024 Dec; 25(1):2321767. PubMed ID: 38417050
[TBL] [Abstract][Full Text] [Related]
19. Natural Products from Microalgae with Potential against Alzheimer's Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors.
Hielscher-Michael S; Griehl C; Buchholz M; Demuth HU; Arnold N; Wessjohann LA
Mar Drugs; 2016 Nov; 14(11):. PubMed ID: 27827845
[TBL] [Abstract][Full Text] [Related]
20. Increased glutaminyl cyclase activity in brains of Alzheimer's disease individuals.
Gunn AP; Wong BX; McLean C; Fowler C; Barnard PJ; Duce JA; Roberts BR;
J Neurochem; 2021 Mar; 156(6):979-987. PubMed ID: 32614980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
